These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31570326)

  • 1. Nivolumab-associated bullous pemphigoid reactions involving multiple epitopes.
    Aoki Y; Miyagawa F; Miyashita K; Nishimura Y; Hashimoto T; Asada H
    Eur J Dermatol; 2019 Oct; 29(5):552-554. PubMed ID: 31570326
    [No Abstract]   [Full Text] [Related]  

  • 2. Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab.
    Kuwatsuka Y; Iwanaga A; Kuwatsuka S; Okubo Y; Murayama N; Ishii N; Hashimoto T; Utani A
    J Dermatol; 2018 Jan; 45(1):e21-e22. PubMed ID: 28944534
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical and dermoscopical presentation of nivolumab-induced pemphigoid in a metastatic melanoma patient.
    Chersi F; Conforti C; Zalaudek I; Bazzacco G; Zelin E; di Meo N
    Melanoma Res; 2023 Jun; 33(3):262-263. PubMed ID: 37114722
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab-induced bullous pemphigoid.
    Ridpath AV; Rzepka PV; Shearer SM; Scrape SR; Olencki TE; Kaffenberger BH
    Int J Dermatol; 2018 Nov; 57(11):1372-1374. PubMed ID: 29624655
    [No Abstract]   [Full Text] [Related]  

  • 5. Cyclosporine for Recalcitrant Bullous Pemphigoid Induced by Nivolumab Therapy for Malignant Melanoma.
    Wallace CE; Tam I; Beveridge MG
    Cutis; 2024 Jul; 114(1):E21-E23. PubMed ID: 39159347
    [No Abstract]   [Full Text] [Related]  

  • 6. Nivolumab-induced bullous pemphigoid after radiotherapy and abscopal effect.
    Grimaux X; Delva R; Jadaud E; Croue A
    Australas J Dermatol; 2019 Aug; 60(3):e235-e236. PubMed ID: 30592031
    [No Abstract]   [Full Text] [Related]  

  • 7. Dyshidrosiform pemphigoid due to nivolumab therapy.
    Hayashi W; Yamada K; Kumagai K; Kono M
    Eur J Dermatol; 2021 Jun; 31(3):411-412. PubMed ID: 34309527
    [No Abstract]   [Full Text] [Related]  

  • 8. Bullous pemphigoid developing upon immune checkpoint inhibition with nivolumab.
    Grän F; Goebeler M; Gesierich A
    Eur J Dermatol; 2019 Aug; 29(4):448-449. PubMed ID: 31625927
    [No Abstract]   [Full Text] [Related]  

  • 9. Bullous pemphigoid induced by pembrolizumab in a patient with advanced melanoma expressing collagen XVII.
    Wada N; Uchi H; Furue M
    J Dermatol; 2017 Oct; 44(10):e240-e241. PubMed ID: 28677843
    [No Abstract]   [Full Text] [Related]  

  • 10. Radiation recall dermatitis associated with nivolumab for metastatic malignant melanoma.
    Korman AM; Tyler KH; Kaffenberger BH
    Int J Dermatol; 2017 Apr; 56(4):e75-e77. PubMed ID: 28102540
    [No Abstract]   [Full Text] [Related]  

  • 11. A case of bullous pemphigoid in a malignant melanoma patient following an increased Th2/Th1 ratio in peripheral blood cells after nivolumab treatment.
    Fukuchi K; Shimauchi T; Fujiyama T; Ito T; Honda T
    Eur J Dermatol; 2023 Oct; 33(5):550-551. PubMed ID: 38297931
    [No Abstract]   [Full Text] [Related]  

  • 12. Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor.
    Kwon CW; Land AS; Smoller BR; Scott G; Beck LA; Mercurio MG
    J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):e349-e350. PubMed ID: 28129461
    [No Abstract]   [Full Text] [Related]  

  • 13. Detection of IgG antibodies to BP180 NC16a and C-terminal domains and LAD-1 in nivolumab-associated bullous pemphigoid.
    Matsui Y; Makino T; Ishii N; Hashimoto T; Shimizu T
    Eur J Dermatol; 2019 Oct; 29(5):554-555. PubMed ID: 31570332
    [No Abstract]   [Full Text] [Related]  

  • 14. Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid.
    Sowerby L; Dewan AK; Granter S; Gandhi L; LeBoeuf NR
    JAMA Dermatol; 2017 Jun; 153(6):603-605. PubMed ID: 28355425
    [No Abstract]   [Full Text] [Related]  

  • 15. Bullous Pemphigoid-like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature.
    Anastasopoulou A; Papaxoinis G; Diamantopoulos P; Christofidou E; Benopoulou O; Stratigos A; Gogas H
    J Immunother; 2018 Apr; 41(3):164-167. PubMed ID: 29309291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bullous pemphigoid exacerbated by nivolumab and temporally rescued with therapeutic plasma exchange.
    Waki Y; Nobeyama Y; Chujo S; Asahina A
    J Dermatol; 2024 May; 51(5):e149-e150. PubMed ID: 38010735
    [No Abstract]   [Full Text] [Related]  

  • 17. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
    Aggarwal P
    Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
    [No Abstract]   [Full Text] [Related]  

  • 18. Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma.
    Amber KT; Valdebran M; Lu Y; De Feraudy S; Linden KG
    J Dtsch Dermatol Ges; 2018 Feb; 16(2):196-198. PubMed ID: 29389067
    [No Abstract]   [Full Text] [Related]  

  • 19. Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab.
    Page B; Borradori L; Beltraminelli H; Yawalkar N; Hunger RE
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e256-e257. PubMed ID: 28430376
    [No Abstract]   [Full Text] [Related]  

  • 20. No recurrence of nivolumab-induced idiopathic thrombocytopenic purpura in a metastatic melanoma patient switched to ipilimumab.
    Takimoto R; Otsuka A; Kaku Y; Honda T; Kabashima K
    Eur J Dermatol; 2018 Feb; 28(1):84-85. PubMed ID: 29400292
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.